Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
David P. Meeker

David P. Meeker

Chairman, Chief Executive, and President of Rhythm Pharmaceuticals

Appears in 1 story

Notable Quotes

"IMCIVREE is now the first and only FDA-approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options." — Statement on FDA approval, March 2026

Stories

FDA expands treatment options for obesity with rare and mainstream drug approvals

New Capabilities

Leading Rhythm through its broadest indication expansion

For patients who gained severe, uncontrollable weight after brain tumor surgery—often as children—there has never been an approved medication. That changed on March 19, 2026, when the Food and Drug Administration (FDA) approved Imcivree (setmelanotide) for acquired hypothalamic obesity, a condition affecting roughly 10,000 Americans whose damaged hypothalamus makes diet and exercise essentially useless. In clinical trials, patients lost 18.4% more body mass than those on placebo over one year. Two weeks later, on April 1, the FDA approved Eli Lilly's Foundayo (orforglipron), the first GLP-1 pill taken without food restrictions, achieving 12.4% weight loss.

Updated Apr 1